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Abstract We analyzed data from a large randomized
HIV/HCV prevention intervention trial with young injection
drug users (IDUs) conducted in five U.S. cities. The trial
compared a peer education intervention (PEI) with a time-
matched, attention control group. Applying categorical latent
variable analysis (mixture modeling) to baseline injection
risk behavior data, we identified four distinct classes of
injection-related HIV/HCV risk: low risk, non-syringe
equipment-sharing, moderate-risk syringe-sharing, and high-
risk syringe-sharing. The trial participation rate did not vary
across classes. We conducted a latent transition analysis
using trial baseline and 6-month follow-up data, to test the
effect of the intervention on transitions to the low-risk class at
follow-up. Adjusting for gender, age, and race/ethnicity, a
significant intervention effect was found only for the high-
risk class. Young IDU who exhibited high-risk behavior at
baseline were 90 % more likely to be in the low-risk class at
follow-up after the PEI intervention, compared to the control
group.
Keywords Injection drug use  Intervention 
HIV  HCV  Latent class analysis
Introduction
Injection drug use is a serious public health problem in the
U.S. and globally, leading to blood-borne infections
including HBV, HCV, and HIV. Although the number of
HIV/AIDS cases in the U.S. due to injection drug use has
declined significantly since its peak in 1993, drug injection
remains a major risk factor [1]. In 2007, an estimated 15 %
of reported HIV cases among adults and adolescents in the
U.S. (N = 9,200) were associated with injection drug use
or sexual contact with injection drug users (IDUs). In
addition, 21 % of reported HIV cases among children
(\13 years) were associated with injection drug use by the
mother or the mother’s sexual partner [2].
Drug injection is also responsible for most HCV trans-
mission in the U.S., and is a major contributor to HBV
transmission [3–5]. Recent surveys suggest that approxi-
mately one-third of young (18–30 years old) IDUs in the
U.S. are HCV-infected, although prevalence varies widely
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[6]. The sharing of contaminated syringes and other
injection equipment is the principal means by which drug
injection exposes users to these viruses [7–11].
Despite significant advances in the prevention of HIV/
AIDS and hepatitis, injection drug use continues to con-
tribute to new infections both directly through the sharing of
injection equipment, and indirectly through sexual trans-
mission from IDUs to non-IDU sex partners [12–15]. Syr-
inge access, opioid substitution therapy, street outreach, and
counseling and testing (C&T) have been identified as
important components in advancing HIV/HCV prevention
[16–22], while enhanced behavioral interventions with IDUs
have shown only modest effects on reducing receptive
injection risk behaviors over and above standard services
(i.e. risk assessment, C&T) [23–25]. However, peer educa-
tion initiatives have demonstrated some success in influ-
encing the behavior of IDUs trained to be peer educators
[26–29]. Spanning five cities, the Third Collaborative Injec-
tion Drug Users Study (CIDUS 3) drug users intervention trial
(DUIT), conducted from 2002 through 2005, is the largest
randomized HIV prevention intervention trial with young
IDUs in the U.S. to date. This study compared a peer education
intervention (PEI) with a time-matched, attention control
group receiving standard counseling and testing.
While the DUIT enhanced intervention demonstrated an
overall greater decrease in injection-related HIV risk
behavior compared to the control [30, 31], not all DUIT
participants reduced their risk behavior. The average effect
conceals a heterogeneous mix of intervention responders
and non-responders. The key to improving interventions
with IDUs may lie in understanding variations in responses
to these interventions. Conventional approaches to the
analysis of intervention effects are based on fitting a
regression model for the average response pattern. How-
ever, when a behavior is highly heterogeneous, it is often
useful to characterize that heterogeneity in order to identify
discrete patterns of change. If we can identify certain
behavioral profiles that are associated with intervention
success, future efforts with that intervention can be targeted
to individuals with that particular profile.
Latent variable mixture models are used to capture this
heterogeneity [32]. Latent class analysis is a person-centered
method for empirically identifying distinct patterns or sub-
types, based on a set of observed categorical variables [33].
Latent transition analysis is an extension of the latent class
model that is used to examine transitions across classes over
time [34, 35]. By incorporating an intervention effect in a
latent transition model, we can test whether the intervention
effect is consistent or varies across classes [36]. In this study,
we used latent variable mixture modeling to: (1) identify
distinct classes of individuals with unique, class-specific
patterns of injection risk behavior, and (2) test variation in
the effectiveness of the intervention across these risk classes.
Methods
Study Design
We analyzed existing CIDUS3 DUIT data collected
between May 2002 and January 2004 from 1569 eligible
participants who were recruited in five US cities: Baltimore
MD, Chicago IL, Los Angeles CA, New York City NY,
and Seattle WA. Details of the study objectives, design and
methodology have been described elsewhere [37, 38].
Participants were eligible for the trial if they reported
injecting illicit drugs in the past 6 months, intended to
reside in their recruitment city for at least the next
12 months, spoke English, were between 15 and 30 years
old, and tested antibody-negative for HIV and HCV at
baseline. Eligible participants who attended the post-test
counseling session where they were invited to participate in
the trial were included in the baseline analysis.
Individuals who consented to participate in the trial
(N = 854) were randomly assigned to either the PEI, or a
video-discussion control group. Participants in both condi-
tions attended six group sessions over a 3-week period. All
participants attended at least the first session; attendance at
each of the remaining sessions was reasonably high and
similar across trial arms (average 77 % for PEI, 78 % for
control). Participants were compensated for time and travel
after each visit, according to local guidelines—$20–$40 for
ACASI interviews, $10–15 for each test result visit, and
$20–25 for each intervention session attended (with four
sites offering a $40 bonus for attending all six sessions).
PEI participants were informed that the purpose of the
intervention was to train them to be peer educators who
could help in the fight against AIDS and hepatitis in their
communities. Talking to others about HIV and HCV pre-
vention, in a pro-social role of peer educator, was expected
to motivate behavior change in the educators [38]. In the
first four sessions, participants learned what it meant to be
a peer educator and were given tools appropriate to this
role. The first two sessions focused on injection-related risk
and the third and fourth sessions focused on sexual risk
behavior. The format included videos; interactive discus-
sions; exercises in skills building, role playing, and prac-
tice; and other factors such as offering community
resources, information, and tools (e.g., condoms) at every
session. In the fifth session, participants were given an
opportunity to practice sharing risk-reduction information
in a community setting, for example, by engaging in
supervised peer outreach or staffing an information table at
a community center or health fair. These experiences were
followed by debriefing and feedback from the intervention
facilitator. The sixth session consisted of a group debriefing
about the community-based peer education session, fol-
lowed by a goal-setting activity.
2076 AIDS Behav (2013) 17:2075–2083
123
The control condition consisted of watching videos fol-
lowed by facilitated discussion for an equivalent amount of
time as the PEI sessions. Videos addressing social and health
issues were chosen to be of interest to the target population,
yet devoid of specific HIV/HCV risk-reduction content.
At baseline and follow-up visits, participants completed
a behavioral assessment using audio computer-assisted
self-interview (ACASI) technology to minimize socially
desirable responding. Retention rates for the 3- and
6-month follow-up visits were 64–76 %, respectively, with
83 % of the sample (N = 712) completing at least one
follow-up interview. Institutional review boards at the
CDC and all collaborating institutions approved the study
protocol, and all individuals provided written, informed
consent to participate in the study.
Measures
Sociodemographic Measures
Respondents provided information on sociodemographic
characteristics, including sex, age, race/ethnicity, homeless-
ness, incarceration, and sources of income (legal and illegal).
Injection Drug Use
Respondents were asked about the types of drugs they
injected, how often they injected, how often they injected
with other IDUs, how many different people they injected
with, and their relationship to the people they injected with.
Injection-Related HIV/HCV Risk
Seven measures of injection risk behavior were included in
this analysis: relative frequency of sharing syringes,
cookers, cotton filters, and rinse water, frequency of using a
new sterile syringe to divide drugs, frequency of cleaning
needles with bleach, and the number of people sharing a
syringe with the respondent. Relative frequency of sharing
syringes and other injection equipment, using new sterile
syringes to divide drugs, and cleaning needles with bleach
were measured on a 7-point Likert-type scale, labeled from
‘‘always’’ to ‘‘never,’’ with ‘‘about half the time’’ as the
midpoint. Measures of ‘‘safe’’ behavior (using new sterile
syringes to divide drugs, and cleaning syringes with
bleach) were reversed so that for all measures higher scores
represented more risky behavior. Since the distributions of
these variables were highly skewed, they were re-coded
into three categories: never, less than half the time, and half
the time or more. The number of injection partners sharing
a syringe with the respondent was also recoded into three
categories: none, one, and more than one.
Analysis
Baseline
The seven categorical measures of injection risk behavior
were used to identify distinct classes of risk behavior.
Using the baseline data from all trial-eligible respondents
(N = 1569), we conducted latent class analyses using
Mplus version 6.1 [39]. We fit models with two to six
classes and compared the log-likelihood and goodness-
of-fit indices. This first step helps to reveal how many
classes fit the data best.
After selecting the best-fitting latent class model, the
class probabilities and most likely class patterns were
further analyzed using Stata version 11. Multinomial
logistic regressions were conducted predicting most likely
class membership from sociodemographic variables,
injection frequency, and HIV/HCV risk knowledge and
attitudes. These analyses provide information about how
the classes differed at baseline, that is, what characteristics
are associated with each class.
As a test of selection bias, the distribution of classes was
compared among participants who were randomized to a
trial condition, and those who were not randomized (i.e.
they either did not consent to trial participation or failed to
show up). This comparison provides information on whe-
ther certain classes of participants were more or less likely
to participate in the trial.
DUIT Trial
The analysis of the DUIT trial used data from 708 partici-
pants who completed at least one follow-up interview and
had non-missing injection risk data. The purpose of this
analysis was to test whether the intervention was equally
effective across classes, or whether some classes were more
responsive than others. First, latent class models with three
to five classes were fit separately for each time point to
verify that the number of classes selected based on the
baseline analysis was appropriate at all points. Then latent
transition models were conducted for baseline to three-
month, and baseline to 6-month follow-up data. Models
with thresholds constrained to be equal over time were
compared with models allowing thresholds to vary, using
the Satorra-Bentler v2 difference test based on log-likeli-
hood values and scaling correction factors obtained with the
MLR estimator in Mplus [40]; see http://www.statmodel.
com/chidiff.shtml. Finally, the intervention effect was
added to the model as a known class, and a model with
thresholds constrained across trial arms was compared with
an unconstrained model. To test for differential response
across classes, the probability of low-risk class membership
at follow-up was analyzed in Stata 11 using a generalized
AIDS Behav (2013) 17:2075–2083 2077
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linear model with a logit transformation, with intervention
arm and the most likely class at baseline, and their inter-
action, as predictors. Marginal effects were computed for
intervention arm within each baseline class.
Results
Sample Demographics
The baseline sample was 33 % female, with a mean age of
23.5 (range 15–30; 38 minors age 15–17). Two-thirds of
respondents were non-Hispanic White, 18 % were His-
panic, 11 % were non-Hispanic Black, and 6 % were other
race/ethnicity. Forty-seven percent reported being home-
less, and 18 % reported being in jail or prison in the past
6 months.
Baseline
Based on model fit indices and log-likelihood change (see
Fig. 1), the four-class model was clearly better than the
three-class model, while the five-class model resulted in a
relatively small improvement over the four-class model.
Although the bootstrap likelihood ratio test indicated that
the five-class model resulted in a significant improvement
in fit (p \ 0.0001), the additional class extracted comprised
\10 % of the sample and we were not convinced that it
contributed substantively to the model. The four-class model
had very good classification quality (Entropy = 0.899), and
the average latent class probabilities for most likely latent
class membership ranged from 0.926 to 0.966. Based on the
fit indices as well as conceptual considerations, we pro-
ceeded with the four-class model.
Figure 2 shows the unique patterns of injection risk
behaviors for each class in the four class model: (1) overall
low risk (33 %), (2) equipment sharing (22 %), (3) mod-
erate risk characterized by low-frequency sharing of
syringes (19 %), and (4) overall high risk (27 %). For each
class, the x-axis includes the seven risk behaviors, and the
y-axis represents the probabilities of high (solid lines) and
low frequency (dashed lines) responses for each risk
behavior. The five-class model (not shown) split the
equipment sharing class into two classes, one that shared
equipment often, and one that shared infrequently.
The low-risk class exhibited very little risk behavior;
about 11 % of individuals in this class shared cookers
less than half the time. In the equipment-sharing class,
40 % shared cookers half the time or more, while 57 %
shared cookers less than half the time. Syringe sharing
was very unlikely in this group, and no one in this group
injected with a used syringe without cleaning it with
bleach. Everyone in the moderate risk class shared syrin-
ges, most (89 %) less than half the time; however only
29 % always cleaned their shared syringes with bleach.
The high-risk class was characterized by high frequency of
sharing equipment, and low or high frequency of syringe
sharing with a majority not cleaning shared syringes with
bleach.
Table 1 shows some demographic and injection-related
characteristics of the four injection risk classes. The high-
risk class had the highest percentage of women, the lowest
mean age, the highest rates of homelessness and income
from illicit activities. The classes did not differ signifi-
cantly on rates of incarceration. The low-risk class was
distinguished by the highest percentages of Hispanic and
Black IDUs and the fewest injection partners. Both the
low-risk and equipment-only classes had lower frequencies
of injections compared to the moderate and high-risk
classes.
Table 2 shows HIV/HCV risk knowledge and attitudes
by injection risk class. The four classes had similar levels
of risk knowledge, but varied in risk perceptions, peer
norms, and self-efficacy for safer injection. The low-risk
class had higher levels of perceived risk than each of the
other classes; peer norms for safer injection (against shar-
ing syringes or equipment) were highest in the low risk
class, and lowest in the high-risk class, with the moderate-
risk and equipment-only classes in between. Self-efficacy
for safer injection decreased steadily with increasing risk
behavior across classes. Class frequencies varied signifi-
cantly across trial sites; Baltimore had a larger proportion
Fig. 1 Goodness of fit measures for latent class models
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of participants in the high-risk class (34 %) than all other
sites. Trial participation did not vary by class membership.
DUIT Trial
The four-class model of injection risk behavior that was fit
to the baseline data also fit the 3-month and 6-month data
well. For the baseline to 3-month latent transition model, a
model with one class free to vary produced a significantly
better fit than the full-invariance model (LR v2, df
14 = 42.03, p \ 0.001). Additionally freeing a second
class resulted in a slightly better fit (LR v2, df 14 = 25.41,
p = 0.031). The baseline to 6-month latent transition
model with invariant thresholds was accepted, as the non-
invariance model did not result in a significantly better fit
(LR v2, df 54 = 62.41, p = 0.20). Given the variations in
class structure, as well as the smaller number of partici-
pants with data at the three-month follow-up, we decided to
focus the analysis on baseline and 6-month follow-up
responses only. The model with thresholds invariant across
trial arms was accepted based on the v2 difference test (LR
v2, df 56 = 59.36, p = 0.35).
The low-risk class increased substantially at follow-up
in both conditions; at baseline the probability of the low-
risk class was 32 % and at follow-up it was 69 %. At the
same time, the high-risk class probability decreased from
24 to 8 %, the moderate-risk class probability decreased
from 21 to 10 %, and the equipment-sharing class
decreased from 23 to 12 %. Latent class transition proba-
bilities for each condition are shown in Table 3. The
diagonal values include participants who remained in the
same class at both time points. For example, the probability
of a low-risk participant remaining in the low-risk class
was 87 % in the control arm and 95 % in the PEI arm. The
marginal effect for this baseline low-risk class reached
significance (dy/dx = 0.069, 95 % CI 0.003–0.14;
z = 2.04, p = 0.041) and remained significant when
adjusted for city, age, race, and sex. The off-diagonal
values represent transition across classes. For example, in
the control arm, the probability of a high-risk participant
transitioning to the low-risk class was 37 %, and in the PEI
arm the probability was 53 %. The marginal effect of
intervention arm for the baseline high-risk class was sta-
tistically significant (dy/dx = 0.157, 95 % CI 0.02–0.29;
z = 2.27, p = 0.023) and remained significant when
adjusted for city, age, race, and sex.
Closer inspection of the most likely class patterns
revealed that the difference in posterior probabilities for the
baseline high-risk participants in the control versus the PEI
condition was possibly due to greater loss-to-follow-up in
the control condition; 13 % of high-risk participants in the
control condition did not return for the 6-month follow-up,
versus 4 % of those in the PEI condition (v2 (1) = 4.13,
p = 0.042). Using complete cases only, the intervention
Fig. 2 Four latent classes of
injection risk behavior
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effect remained significant for baseline high-risk partici-
pants (dy/dx = 0.16, 95 % CI 0.01–0.31, z = 2.10,
p = 0.036), however the effect for baseline low-risk par-
ticipants did not (p = 0.061).
Discussion
In this sample of young IDUs recruited in five different
cities, we identified four distinct classes of injection risk
behavior. One-third of the sample exhibited little or no risk
behavior (low risk) at baseline. Another group was char-
acterized by sharing mainly equipment other than syringes;
participants in this class either refrained from sharing
syringes, or always cleaned the syringes with bleach. The
third class (moderate risk) was characterized by low
frequency sharing of syringes and equipment. Participants
in the high-risk group shared equipment frequently, shared
syringes at least some of time, and were more likely to
share syringes frequently.
The latent transition analysis indicated that the DUIT
PEI intervention was most beneficial for young IDUs who
exhibited high-risk behavior. The PEI was marginally more
effective than the control intervention for maintaining low-
risk behavior, and had no significant effect among IDUs in
the moderate-risk and equipment-sharing classes. Individ-
uals in these lower risk classes were likely to switch to low-
risk behavior regardless of the intervention, with about
two-thirds transitioning to the low-risk class. Theoretical
explanations of risk reduction among peer interventionists
have included cognitive consistency, social identity theory,
and social reinforcement [27, 41–43]. Developing a pro-
Table 1 Baseline
characteristics of four latent
classes of injection risk
behavior
a In the past 6 months, have
you slept in a car, abandoned
building, public park, shelter,
squatting place, or other non-
dwelling for more than 7 nights
in a row?
b Past 3 months
LR v2 = Likelihood ratio v2
from multinomial logistic
regression










Mean 23.92 23.67 23.35 22.92 19.90 0.0002 1560
Std Err 0.16 0.19 0.21 0.17
Gender (%)
Male 74.18 64.29 70.59 58.17 29.56 \0.0001 1560
Female 25.82 35.71 29.41 41.83
Race/ethnicity (%)
White 58.57 68.45 69.55 70.67 25.64 0.0023 1560
Black 14.64 10.42 9.00 7.21
Hispanic 20.81 16.67 14.88 17.07
Other 5.97 4.46 6.57 5.05
Homeless past
6 months (%)
41.39 50.15 46.37 51.44 11.23 0.0106 1557
Slept in non-
dwelling (%)a
33.08 39.29 36.81 46.39 17.70 0.0005 1557
Ever incarcerated
(%)
73.03 66.37 70.59 65.87 7.29 0.0633 1560
Incarcerated past
6 months (%)
16.54 16.87 19.01 19.32 1.70 0.6380 1544
Job income (%) 57.23 68.45 62.98 60.82 11.33 0.0101 1560
Illicit activity
income (%)
37.76 44.64 48.10 55.05 28.74 \0.0001 1560
Times injectedb
Mean 165.34 186.69 224.46 250.84 45.96 \0.0001 1542
Std Err 8.22 8.79 13.11 11.78
People injected withb
Mean 2.69 4.45 5.28 5.52 72.57 \0.0001 1530
Std Err 0.28 0.30 0.44 0.34
Times injected with othersb
Mean 43.67 80.14 101.69 150.83 124.41 \0.0001 1435
Std Err 4.59 6.63 10.93 10.29
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social identity, positive social reinforcement from com-
munity members, and cognitive dissonance associated with
continued risk behavior, can influence motivation and self-
efficacy for risk reduction [41]. For IDUs with high-risk
behavior, the PEI may provide the social-cognitive stimu-
lus they need to move to a higher level of motivational
readiness for behavior change [44, 45]—to move from
contemplation to preparation, and from preparation to
action. IDUs with lower levels of risk behavior may
respond just as well to less intensive interventions.
These results suggest that targeting the PEI intervention
to young IDUs with a high-risk profile may be an efficient
approach. One caveat however, is that intervening with a
uniform group of high-risk IDUs may produce different
results than with a mixed group of various risk levels.
There may be some unmeasured group dynamics involved
that influence the outcomes. Also, this analysis did not
address the relationship between behavior change and
observed HIV or HCV infection. Reductions in the use of
shared syringes and other equipment should in theory lead
to fewer infections, however it may be difficult to dem-
onstrate such an effect without very large samples and
sufficient follow-up time [26]. Behavioral interventions
should be considered as one part of a multi-component strat-
egy to address HIV and HCV prevention among IDUs [46].
It is important to note that young IDUs of all types were
included in the trial. High-risk young IDUs were no more
or less willing to participate in the intervention than their
low-risk peers. However, the large proportion of low-risk
participants included in the trial raises concerns. On one
hand, maintaining low-risk behavior may be as important
as preventing high-risk behavior. On the other hand, if
individuals with low-risk behavior generally remain low-
risk, the power of the study is compromised by including
them in the trial. Moreover, when implementing a pre-
vention program, focusing resources on the high-risk
groups may be the most cost effective approach.
The demographic and behavioral characteristics of the
risk classes are consistent with previous research [47–50].
IDUs in the high-risk class were younger, and more likely
to be female, White, have unstable housing, and income
from illicit activities, and injected more often compared to
those in the low-risk class. The moderate-risk and equip-
ment-only classes generally had demographic and behavior
patterns in between the two extreme groups and similar to
Table 2 Baseline HIV/HCV risk knowledge and attitudes by injec-
tion risk class










Mean 64.25 66.03 65.69 65.50
Adj RRRa 1.00 1.00 1.00 1.00
95 % CI (1.00–1.01) (0.99–1.01) (0.99–1.01)
HIV/HCV risk perception***
Mean 4.24 3.92 3.93 3.80
Adj RRR 1.00b 0.59c 0.61c 0.51c
95 % CI (0.49–0.70) (0.51–0.74) (0.43–0.60)
Peer norms: needles***
Mean 0.49 0.36 0.33 0.24
Adj RRR 1.00b 0.73c 0.67c 0.50d
95 % CI (0.57–0.93) (0.52–0.86) (0.39–0.64)
Peer norms: paraphernelia***
Mean 0.42 0.20 0.24 0.09
Adj RRR 1.00b 0.55c 0.63c 0.41d
95 % CI (0.44–0.70) (0.50–0.81) (0.33–0.53)
Self-efficacy safe injection***
Mean 3.54 3.27 2.90 2.70
Adj RRR 1.00b 0.48c 0.24d 0.18e
95 % CI (0.38–0.61) (0.19–0.31) (0.14–0.22)
*** Model LR v2, p \ 0.001
a Relative-risk ratio, adjusted for gender, age, race/ethnicity
b,c,d,e Estimates with different superscripts are significantly different,
p \ 0.05
Table 3 Probabilities of class membership at follow-up by baseline class and intervention arm
Baseline classa Control (N = 343) PEI (N = 365)
Low Equipment Moderate High Low Equipment Moderate High
Low 87 % 5 % 3 % 5 % 95 % 0 % 3 % 2 %
Equipment 71 18 7 4 64 26 7 3
Moderate 61 11 22 6 68 6 18 8
High 37 22 16 25 53 18 15 14
Diagonal values are percentages of participants who remained in the same class from baseline to follow-up; off-diagonal values are percentages
of participants transitioning across classes
Bolded values are significantly different (p \ 0.05)
a Most likely class based on posterior probabilities
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each other. However, on number of injection partners, the
low-risk class differed from the other three classes which
were all similar to one another. In terms of psychosocial
variables, the high-risk class had the lowest levels of per-
ceived risk, and peer norms and self-efficacy for safer
injection. These constructs might be useful as proxy mea-
sures of risk behavior for selecting intervention
participants.
Conclusions
The results of this analysis indicate that the PEI had a
significant impact on self-reported injection behavior
among young IDUs with high-risk injection behavior. For
young IDUs who are not high-risk, standard counseling and
testing interventions may be as effective as enhanced
interventions. Targeting the PEI to high-risk young IDUs
may achieve significant behavior change at a lower cost.
Acknowledgments This study was supported by a grant from the
National Institute on Drug Abuse, R01 DA031584. The CIDUS-3/
DUIT intervention trial was supported by a cooperative agreement
from the Centers for Disease Control and Prevention U64/
CCU317662, U64/CCU517656, U64/CCU917655, U64/CCU217659,
U64/CCU017615; Institutional Review Board no. CDC-NCHSTP-
2934. The findings and conclusions in this report are those of the
authors and do not necessarily represent the views of the National
Institute on Drug Abuse or the Centers for Disease Control and Pre-
vention. The DUIT Study Group includes the following people:
Steffanie Strathdee, Elizabeth Golub, Marie Bailey-Kloch and Karen
Yen-Hobelman (Baltimore); Lawrence Ouellet, Susan Bailey and
Joyce Fitzgerald (Chicago); Sharon Hudson, Peter Kerndt and Karla
Wagner (Los Angeles); Mary Latka, David Vlahov and Farzana
Kapadia (New York); Holly Hagan, Hanne Thiede, Nadine Snyder and
Jennifer V. Campbell (Seattle); and Richard Garfein, David Purcell,
Ian Williams, Paige Ingram and Andrea Swartzendruber (CDC). We
thank Dr. Katie Witkiewitz for her expert assistance with the analysis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Santibanez S, Garfein R, Swartzendruber A, Purcell D, Paxton L,
Greenberg A. Update and overview of practical epidemiologic
aspects of HIV/AIDS among injection drug users in the United
States. J Urban Health. 2006;83(1):86–100.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveil-
lance Report, 2007. Vol. 19. Atlanta, GA: U.S. Department of
Health and Human Services; 2009. Available from http://www.
cdc.gov/hiv/topics/surveillance/resources/reports.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J
Gastroenterol. 2007;13:2436–41.
4. Institute of Medicine. Hepatitis and liver cancer: a national
strategy for prevention and control of Hepatitis B and C. Wash-
ington DC.: The National Academies Press; 2010.
5. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER.
Hepatitis C virus infection: prevalence, risk factors, and pre-
vention opportunities among young injection drug users in Chi-
cago, 1997–1999. J Infect Dis. 2000;182(6):1588–94.
6. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet
LJ, Latka MH, et al. Prevalence of Hepatitis C virus infection
among injection drug users in the United States, 1994–2004. Clin
Infect Dis. 2008;46(12):1852–8.
7. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral
infections in short-term injection drug users: the prevalence of the
hepatitis C, hepatitis B, human immunodeficiency, and human
T-lymphotropic viruses. Am J Public Health. 1996;86(5):655–61.
8. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alex-
ander ER. Syringe exchange and risk of infection with hepatitis B
and C viruses. Am J Epidemiol. 1999;149(3):203–13.
9. Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepat.
1995;2(3):113–9.
10. Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart
ML, Montaner JSG, et al. Needle exchange is not enough: lessons
from the Vancouver injecting drug use study. AIDS. 1997;11(8):
F59–65.
11. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT,
Williamson J, et al. Risk of hepatitis C virus infection among
young adult injection drug users who share injection equipment.
Am J Epidemiol. 2002;155(7):645–53.
12. Thiede H, Hagan H, Campbell JV, Strathdee SA, Bailey SL,
Hudson SM, et al. Prevalence and correlates of indirect sharing
practices among young adult injection drug users in five U.S.
cities. Drug Alcohol Depend. 2007;91(Suppl. 1):S39–47.
13. Centers for Disease Control and Prevention. HIV-associated
behaviors among injecting drug users—23 cities, United States,
May 2005–February 2006. Morb Mortal Wkl Rep. 2009;58(13):
329–32.
14. Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syr-
inge coverage is associated with lower odds of HIV risk and does
not increase unsafe syringe disposal among syringe exchange
program clients. Drug Alcohol Depend. 2007;89(2–3):214–22.
15. Huo D, Ouellet LJ. Needle exchange and sexual risk behaviors
among a cohort of injection drug users in Chicago, Illinois. Sex
Transm Dis. 2009;36(1):35–40.
16. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Bea-
trice S, et al. Reductions in hepatitis C virus and HIV infections
among injecting drug users in New York City, 1990–2001. AIDS.
2005;19(Suppl. 3):S20–5.
17. Coyle SL, Needle RH, Normand J. Outreach-based HIV pre-
vention for injecting drug users: a review of published outcome
data. Public Health Rep. 1998;113(Suppl. 1):19–30.
18. Wodak A, Cooney A. Do needle syringe programs reduce HIV
infection among injecting drug users: a comprehensive review of
the international evidence. Subst Use Misuse. 2006;41(6–7):
777–813.
19. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe
exchange programs in reducing HIV risk behavior and HIV
seroconversion among injecting drug users. AIDS. 2001;15(11):
1329–41.
20. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The
effect of syringe exchange use on high-risk injection drug users: a
cohort study. AIDS. 2000;14(5):605–11.
21. Marshall BDL, Wood E. Toward a comprehensive approach to
HIV prevention for people who use drugs. J Acquir Immune
Defic Syndr. 2010;55(Suppl. 1):S23–6.
22. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV
prevention strategy: a review. Drug Alcohol Depend. 2000;59(1):
17–31.
23. Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/
AIDS interventions on drug use and needle risk behaviors for out-
2082 AIDS Behav (2013) 17:2075–2083
123
of-treatment injection drug users. J Psychoact Drugs.
1998;30(3):269–78.
24. Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL.
Effectiveness of brief counseling in reducing HIV risk behavior in
injecting drug users: final results of randomized trials of counseling
with and without HIV testing. AIDS Behav. 1999;3(1):3–12.
25. Meader N, Ryan L, Des Jarlais DC, Pilling S. Psychosocial
interventions for reducing injection and sexual risk behaviour for
preventing HIV in drug users. Cochrane Database Syst Rev.
2010; (1). doi:10.1002/14651858.CD007192.pub2.
26. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural
interventions for preventing hepatitis C infection in people who
inject drugs: a global systematic review. Int J Drug Policy.
2012;23(3):176–84.
27. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug
users: outcome of a network-oriented peer outreach intervention.
Health Psychol. 2003;22(4):332–9.
28. Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell
JV, et al. A randomized intervention trial to reduce the lending of
used injection equipment among injection drug users infected
with hepatitis C. Am J Public Health. 2008;98(5):853–61.
29. Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The
STEP into Action study: a peer-based, personal risk network-
focused HIV prevention intervention with injection drug users in
Baltimore, Maryland. Addiction. 2011;106(2):366–75.
30. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL,
Hudson SM, et al. A peer-education intervention to reduce
injection risk behaviors for HIV and hepatitis C virus infection in
young injection drug users. AIDS. 2007;21(14):1923–32.
31. Mackesy-Amiti ME, Ouellet LJ, Golub ET, Hudson S, Hagan H,
Garfein RS. Predictors and correlates of reduced frequency or
cessation of injection drug use during a randomized HIV pre-
vention intervention trial. Addiction. 2011;106(3):601–8.
32. Muthe´n B. Latent variable modeling in heterogeneous popula-
tions. Psychometrika. 1989;54(4):557–85.
33. McCutcheon AL. Latent class analysis. Newbury Park: Sage;
1987.
34. Collins LM, Wugalter SE. Latent class models for stage-sequen-
tial dynamic latent-variables. Multivar Behav Res. 1992;27(1):
131–57.
35. Lanza ST, Flaherty BP, Collins LM. Latent class and latent
transition analysis. Handbook of psychology. Hoboken: Wiley;
2003.
36. Collins LM, Graham JW, Rousculp SS, Fidler PL, Pan J, Hansen
WB. Latent transition analysis and how it can address prevention
research questions. In: Collins LM, Seitz LA, editors. Advances
in data analysis for prevention intervention research. Rockville:
U.S. Department of Health and Human Services; 1994.
37. Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson
SM, Thiede H, et al. Methods to recruit and retain a cohort of
young-adult injection drug users for the Third Collaborative
Injection Drug Users Study/Drug Users Intervention Trial
(CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl. 1):
S4–17.
38. Purcell DW, Garfein RS, Latka MH, Thiede H, Hudson S, Bonner S,
et al. Development, description, and acceptability of a small-group,
behavioral intervention to prevent HIV and hepatitis C virus infec-
tions among young adult injection drug users. Drug Alcohol Depend.
2007;91(Suppl. 1):S73–80.
39. MPlus [computer program]. Muthe´n & Muthe´n; Ver. 6.1, 2010.
40. Satorra A, Bentler PM. A scaled difference Chi-square test sta-
tistic for moment structure analysis. UCLA Department of Sta-
tistics, 1999. Available from http://preprints.stat.ucla.edu.
41. Dickson-Gomez J, Weeks MR, Convey M, Jianghong L. Social
psychological dynamics of enhanced HIV risk reduction among
peer interventionists. J Community Psychol. 2011;39(4):369–89.
42. Fisher JD, Misovich S. Social influence and AIDS-preventive
behavior. In: Edwards J, Tindale RS, Heath L, Posavac EJ, edi-
tors. Social influence processes and prevention. New York: Ple-
num Press; 1990. p. 39–70.
43. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL,
Madray H, Mills RJ, et al. Harnessing peer networks as an
instrument for AIDS prevention: results from a peer-driven
intervention. Public Health Rep. 1998;113(Suppl. 1):42–57.
44. Prochaska JO, DiClemente CC, Norcross JC. In search of how
people change: applications to addictive behaviors. Am Psychol.
1992;47(9):1102–14.
45. Prochaska JO, Redding CA, Harlow LL, Rossi JS, Velicer WF.
The transtheoretical model of change and HIV prevention: a
review. Health Educ Behav. 1994;21(4):471–86.
46. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C,
Hickman M. Prevention of HIV infection for people who inject
drugs: why individual, structural, and combination approaches
are needed. The Lancet. 2010;376(9737):285–301.
47. Huo D, Bailey SL, Garfein RS, Ouellet LJ. Changes in the
sharing of drug injection equipment among street-recruited
injection drug users in Chicago, Illinois, 1994–1996. Subst Use
Misuse. 2005;40(1):63–76.
48. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ.
Injection-related risk behaviors in young urban and suburban
injection drug users in Chicago (1997–1999). J Acquir Immune
Defic Syndr. 2001;27(1):71–8.
49. Sherman SG, Latkin CA, Gielen AC. Social factors related to
syringe sharing among injecting partners: a focus on gender.
Subst Use Misuse. 2001;36(14):2113–36.
50. Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S.
Correlates of needle sharing among injection-drug users. Am J
Public Health. 1994;84(6):920–3.
AIDS Behav (2013) 17:2075–2083 2083
123
